Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Inclusion criteria

• . Subject has at least a 6 month history of migraine (with or without aura) and including the following:
• . 14 or less headache days per month during the 3 month period prior to the Screening Visit
• . 6 or more migraine days during the Observation Period
• . 14 or less headache days during the Observation Period
• . Pediatric Migraine Disability Assessment Scale (PedMIDAS) Disability Score of \>10 to ≤50, indicating mild (score of 11 to 30) or moderate (score of 31 to 50) disruption in daily activities, as assessed at the Baseline (Randomization) Visit
• . Ability to verbally distinguish migraine attacks from tension/cluster or other types of headaches
• . Migraine attacks, on average, lasting 4 - 72 hours if untreated
• . Subjects on prophylactic migraine medication are permitted to remain on therapy if the dose has been stable for at least 3 months (12 weeks) prior to the Screening Phase, and the dose is not expected to change during the course of the study. 2) Male and female subjects ≥ 6 to \<18 years; subjects must be less than 18 at the time of signing assent / consent.

Exclusion criteria